Alirocumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Alirocumab
- Alirocumab: From Dyslipidaemia and Atherosclerosis to X-linked Ichthyosis (without Steroid Sulfatase Deficiency)
Alirocumab: From Dyslipidaemia and Atherosclerosis to X-linked Ichthyosis (without Steroid Sulfatase Deficiency)
One-Sentence Summary
Alirocumab is a monoclonal antibody against PCSK9, used to lower LDL cholesterol in dyslipidaemia and atherosclerotic cardiovascular disease. The TxGNN model predicts it may be effective for X-linked ichthyosis without steroid sulfatase deficiency, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Dyslipidaemia and atherosclerosis-related disorders (arteriosclerosis, atherosclerosis, arteriolosclerosis), per the knowledge graph; the Singapore licence records do not state an indication |
| Predicted New Indication | Ichthyosis, X-linked, without steroid sulfatase deficiency |
| TxGNN Prediction Score | 99.43% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Alirocumab is a fully human antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 normally promotes degradation of the LDL receptor. Blocking it lets more LDL receptors recycle to the liver cell surface, so more LDL cholesterol is cleared from the blood. The data compiled for this report did not include a detailed mechanism-of-action entry, but this target and mechanism are well established.
The link to X-linked ichthyosis is weak and speculative. This skin condition is associated with cholesterol sulfate accumulation and disrupted skin-barrier lipids. That is only loosely related to LDL-receptor-mediated cholesterol clearance, and there is no direct evidence that PCSK9 inhibition changes skin barrier lipids or ichthyosis. The high score (99.43%) most likely reflects proximity in the knowledge graph's lipid-metabolism network rather than a validated mechanism.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN15229P | Praluent solution for injection in a pre-filled pen 150 mg/ml | Injection, solution |
| SIN15228P | Praluent solution for injection in a pre-filled pen 75 mg/ml | Injection, solution |
Both registrations are valid single-ingredient products. The approved indication text is not recorded in the licence data.
Safety Considerations
Please refer to the package insert for safety information. The only interaction data compiled is the drug's pharmacological target (PCSK9), not drug-drug interactions, and no label warnings or contraindications were available.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone. There are no trials or publications, and the mechanistic link between PCSK9 inhibition and X-linked ichthyosis is speculative. Alirocumab is already marketed in Singapore, so access is not a barrier, but there is no evidence yet to justify further investment in this indication.
To proceed, the following is needed:
- Preclinical or mechanistic evidence that PCSK9 inhibition affects skin barrier lipids or cholesterol sulfate handling in X-linked ichthyosis
- A literature and trial search specific to this condition, which currently returns nothing
- The Singapore package insert, to confirm warnings, contraindications and approved indications
- A comparison with other predictions for this drug that have more plausible lipid-related links, such as xanthomatosis (supported only by case reports) and cholesterol catabolic process disease (largely an extension of existing indications)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.